Abbvie (ABBV) To Benefit from Imbruvica Patents Now Good Until 2032 - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $116.00 price target on Abbvie (NYSE: ABBV) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
